Proteonomix Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2008
2009
2010
2011
Net Income before Extraordinaries
4,969.40
3,858.00
3,470.00
1,383.80
Depreciation, Depletion & Amortization
13.90
13.90
244.60
377.10
Other Funds
111.50
305.50
680.80
-
Funds from Operations
873.80
1,030.50
1,273.30
715.70
Changes in Working Capital
762.40
824.70
708.00
438.40
Net Operating Cash Flow
111.40
205.80
565.30
277.20
Capital Expenditures
-
-
215.30
38.30
Net Investing Cash Flow
-
-
215.30
38.30
Issuance/Reduction of Debt, Net
-
-
-
315.50
Net Financing Cash Flow
111.50
305.50
680.80
315.50
Net Change in Cash
0.10
99.70
99.80
0.00
Free Cash Flow
111.40
205.80
565.30
277.20
Miscellaneous Funds
0.00
0.00
0.00
-

About Proteonomix

View Profile
Address
140 East Ridgewood Avenue
Paramus New Jersey 07652
United States
Employees -
Website mailto:[email protected]
Updated 07/08/2019
Proteonomix, Inc. is a biotechnology company which engages in the discovery and development of stem cell therapeutic and cosmeceutical products. It develops pre clinical-stage therapeutic agents and treatments for diabetes, heart, and lung diseases. Proteonomix was founded by Michael Moshe Cohen on June 26, 1995 and is headquartered in Hawthorne, NJ.